Luminex Corporation Launches xPONENT(TM) Software and MagPlex(TM) Magnetic Microspheres
March 13 2007 - 10:00AM
PR Newswire (US)
New Software and Magnetic Microspheres Advance Company's xMAP(R)
Multiplexing Technology AUSTIN, Texas, March 13
/PRNewswire-FirstCall/ -- Luminex Corporation (NASDAQ:LMNX)
introduces two new key products -- xPONENT, a new, more intuitive
software interface which simplifies the user experience, and
MagPlex microspheres, which add a magnetic component to the
company's core xMAP microsphere technology, enabling use on
automation equipment. xPONENT and MagPlex will enhance both
ease-of-use and automation capabilities expanding xMAP
functionality in the company's core market segments Luminex's
xPONENT Software was developed with experts in human factors and
ergonomic design. Customer-centric development and extensive field
testing with customers has resulted in a user experience which is a
significant step forward in the market place. The software suite
incorporates over 300 new features all designed to simplify
laboratory workflow and increase productivity. New features include
enhanced security (21 CFR Part 11 compliance and electronic
signatures), integration capabilities that allow users to transmit
and receive data from Laboratory Information Systems (LIS/LIMS),
integration with the most popular automated sample preparation
systems, the ability to run magnetic bead applications and
touch-screen capability. xPONENT will be sold on new Luminex
systems and will be available as an upgrade to the over 4100
existing Luminex 100 and 200 systems in the marketplace. Luminex's
MagPlex Microspheres feature super-paramagnetic properties that
make them ideal for running automated xMAP-based assays. These
microspheres can be moved or held in place by a magnetic field.
Many automated sample preparation systems utilize magnetic
properties to automate the sample preparation steps in an assay.
Automating sample testing using MagPlex microspheres on a robotic
sample preparation system will minimize hands-on technician time,
improve precision, and streamline workflow. Gregory J. Gosch, vice
president of marketing and sales at Luminex, said, "Ease-of-use and
automation are very important product criteria for customers in our
targeted market segments, particularly those in high-volume testing
laboratories. We believe the automation capabilities offered by our
MagPlex microspheres and the intuitive design of our xPONENT
software are significant advances in automation and ease-of-use for
both Luminex and multiplexing technologies in general." Luminex's
xMAP multiplexing technology allows researchers to perform numerous
tests simultaneously for detection of gene sequences, protein
interactions and other biological reactions, which are read in a
compact analyzer. xMAP provides significant efficiencies versus
traditional methods which require performing one test at a time.
About Luminex Luminex Corporation develops, manufactures and
markets proprietary biological testing technologies with
applications throughout the life sciences industry. The Company's
xMAP(R) system is an open-architecture, multi-analyte technology
platform that delivers fast, accurate and cost-effective bioassay
results to markets as diverse as pharmaceutical drug discovery,
clinical diagnostics and biomedical research, including the
genomics and proteomics research markets. The Company's xMAP
technology is sold worldwide and is already in use in leading
research laboratories as well as major pharmaceutical, diagnostic
and biotechnology companies. Luminex's xMAP technology received the
2005 Clinical Diagnostics Technology of the Year Award from Frost
& Sullivan. The Company was named in the 2005 Deloitte Fast 500
of fastest-growing technology companies. Further information on
Luminex Corporation or xMAP can be obtained on the Internet at
http://www.luminexcorp.com/. Statements made in this release that
express Luminex's or management's intentions, plans, beliefs,
expectations or predictions of future events are forward-looking
statements. The words "believe," "expect," "intend," "estimate,"
"anticipate," "will," "could," "should" and similar expressions are
intended to further identify such forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995.
It is important to note that the Company's actual results or
performance could differ materially from those anticipated or
projected in such forward-looking statements. Factors that could
cause Luminex's actual results or performance to differ materially
include risks and uncertainties relating to, among others, market
demand and acceptance of Luminex's products, the Company's
dependence on strategic partners for development, commercialization
and distribution of products, concentration of the Company's
revenue in a limited number of strategic partners, fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle
and bulk purchases of consumables, Luminex's ability to scale
manufacturing operations and manage operating expenses, gross
margins and inventory levels, potential shortages of components,
competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's
strategic operating plans, risks and uncertainties associated with
implementing our acquisition strategy and the ability to integrate
acquired companies or selected assets into our consolidated
business operations, as well as the risks discussed under the
heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q,
as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment
of Luminex as of the date of this press release, and Luminex
expressly disclaims any intent, obligation or undertaking to
release publicly any updates or revisions to any forward- looking
statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. Corporate Contact: Harriss
T. Currie Vice President, Finance and Chief Financial Officer
512-219-8020 Media Contact: Nicole L. Cottrill Seigenthaler Public
Relations 615-327-7999 DATASOURCE: Luminex Corporation CONTACT:
Corporate, Harriss T. Currie, Vice President, Finance and Chief
Financial Officer of Luminex Corporation, +1-512-219-8020, or ; or
Media, Nicole L. Cottrill of Seigenthaler Public Relations,
+1-615-327-7999, or , for Luminex Corporation Web site:
http://www.luminexcorp.com/
Copyright
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Sep 2023 to Sep 2024